Cardiovascular medications frequently lead the polypharmacy category, often contributing to adverse clinical outcomes, and the most vulnerable among us are often prescribed the most complex regimens. In a recent article in Cardiology magazine, members of ACC's CV Team Member Section explore the challenges of polypharmacy and strategies to address the ongoing polypharmacy pandemic. Read more.